Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

126.76USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$126.76
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,416,940
52-wk High
$148.32
52-wk Low
$122.15

Select another date:

Wed, Apr 18 2018

Photo

Kentucky accuses J&J of contributing to opioid epidemic

Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.

UPDATE 1-Kentucky accuses J&J of contributing to opioid epidemic

April 18 Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.

Kentucky accuses J&J of contributing to opioid epidemic

April 18 Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.

CORRECTED-UPDATE 1-J&J quarterly profit beats on demand for cancer drugs

April 17 Johnson & Johnson reported a better-than-expected first-quarter profit on Tuesday and raised its full-year sales forecast, helped by growing demand for its cancer drugs.

BRIEF-J&J Says Estimates About 70% Of Cumulative Pre-Tax Costs Relating To Global Supply Chain Actions Will Result In Cash Outlays

* J&J SAYS ESTIMATES THAT ABOUT 70% OF CUMULATIVE PRE-TAX COSTS RELATING TO GLOBAL SUPPLY CHAIN ACTIONS WILL RESULT IN CASH OUTLAYS - SEC FILING Source text: (https://bit.ly/2H9L0dv) Further company coverage:

BRIEF-J&J Posts Q1 Adj Non-Gaap EPS $2.06

* Q1 EARNINGS PER SHARE VIEW $2.02 -- THOMSON REUTERS I/B/E/S

Johnson & Johnson quarterly sales rise 12.6 pct

April 17 Healthcare conglomerate Johnson & Johnson on Tuesday posted a 12.6 percent rise in quarterly sales, helped by strong demand for its cancer drugs.

J&J Baby Powder litigation takes new focus with asbestos claims

NEW YORK A $117 million verdict against Johnson & Johnson and a supplier in favor of a man who said his asbestos-related cancer was caused by long-term use of J&J's Baby Powder could open a new front for thousands of cases claiming the widely-used product caused cancer, legal experts and plaintiffs lawyers said.

J&J, Imerys unit must pay $117 million in New Jersey asbestos cancer case

NEW YORK Johnson & Johnson and Imerys Talc America, a unit of Imerys SA , must pay $117 million in damages in a case involving a man who said he developed cancer due to his exposure to asbestos in talc-based products, a New Jersey state court jury said on Wednesday.

J&J, Imerys unit must pay $117 million in N.J. asbestos cancer case

NEW YORK Johnson & Johnson and Imerys Talc America, a unit of Imerys SA, must pay $117 million in damages in a case involving a man who said he developed cancer due to his exposure to asbestos in talc-based products, a New Jersey state court jury said on Wednesday.

Select another date: